Kinnate Biopharma upsizes IPO and prices above range at $20 a share

Kinnate Biopharma KNTE, -5.03% upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the 11.5 million it originally planned, to raise $240 million. Kinnate has applied to list on Nasdaq, under the ticker "KNTE."